SPH3127 (Mitsubishi Tanabe and Shanghai Pharmaceuticals) is an oral direct renin inhibitor (DRI) being developed for hypertension. The renin-angiotensin-aldosterone system is responsible for regulating blood pressure. Existing drugs treat hypertension by targeting angiotensin-converting enzyme (ACE) and the angiotensin II receptor [...]
5 minute read
Sep. 28, 2022
SPH3127: an Oral Direct Renin Inhibitor (DRI) for Hypertension
SPH3127
oral Renin Inhibitor Ph. III candidate in essential hypertension SBDD and PK profile opt J. Med. Chem. Mitsubishi Tanabe, Yokohama, JPShanghai Pharmaceuticals, Shanghai, CN